Sanix Formulation Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 02-11-2024
- Paid Up Capital ₹ 1.50 M
as on 02-11-2024
- Company Age 4 Year, 4 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 174.64%
(FY 2023)
- Profit -11702.09%
(FY 2023)
- Ebitda -471.78%
(FY 2023)
- Net Worth -191.17%
(FY 2023)
- Total Assets 75.54%
(FY 2023)
About Sanix Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ritu Agrawal and Atul Agrawal serve as directors at the Company.
- CIN/LLPIN
U33119GJ2020PTC118940
- Company No.
118940
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Dec 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sanix Formulation Private Limited offer?
Sanix Formulation Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Common Disease Medicines, Pharmaceutical Tablets, Die Casting Mould & Moulding Tools, Injection Moulds, Psychotherapeutic Agents, Cardiovascular Drugs & Medication, Blood Pressure Medicine, Antiepileptic Drugs.
Who are the key members and board of directors at Sanix Formulation?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritu Agrawal  | Director | 18-Dec-2020 | Current |
| Atul Agrawal | Additional Director | 15-Jul-2023 | Current |
Financial Performance of Sanix Formulation.
Sanix Formulation Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 174.64% increase. The company also saw a substantial fall in profitability, with a 11702.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 191.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sanix Formulation?
Unlock access to Sanix Formulation's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sanix Formulation?
Sanix Formulation has a workforce of 41 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sanix Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sanix Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
